d-jnki-1 and Alzheimer-Disease

d-jnki-1 has been researched along with Alzheimer-Disease* in 3 studies

Other Studies

3 other study(ies) available for d-jnki-1 and Alzheimer-Disease

ArticleYear
Brimapitide Reduced Neuronal Stress Markers and Cognitive Deficits in 5XFAD Transgenic Mice.
    Journal of Alzheimer's disease : JAD, 2018, Volume: 63, Issue:2

    Alzheimer's disease (AD) is characterized by accumulations of amyloid-β (Aβ42) and hyperphosphorylated tau proteins, associated with neuroinflammation, synaptic loss, and neuronal death. Several studies indicate that c-Jun N-terminal kinase (JNK) is implicated in the pathological features of AD. We have investigated in 5XFAD mice, the therapeutic effects of Brimapitide, a JNK-specific inhibitory peptide previously tested with higher concentrations in another AD model (TgCRND8). Three-month-old 5XFAD and wild-type littermate mice were treated by intravenous injections of low doses (10 mg/kg) of Brimapitide every 3 weeks, for 3 or 6 months (n = 6-9 per group). Cognitive deficits and brain lesions were assessed using Y-maze, fear-conditioning test, and histological and biochemical methods. Chronic treatment of Brimapitide for 3 months resulted in a reduction of Aβ plaque burden in the cortex of 5XFAD treated mice. After 6 months of treatment, cognitive deficits were reduced but also a significant reduction of cell death markers and the pro-inflammatory IL-1β cytokine in treated mice were detected. The Aβ plaque burden was not anymore modified by the 6 months of treatment. In addition to modulating cognition and amyloid plaque accumulation, depending on the treatment duration, Brimapitide seems experimentally to reduce neuronal stress in 5XFAD mice.

    Topics: Alzheimer Disease; Animals; Brain; Cell Death; Cognition; Disease Models, Animal; Humans; Learning; Male; MAP Kinase Kinase 4; Mice, Transgenic; Neurons; Neuroprotective Agents; Nootropic Agents; Peptides; Plaque, Amyloid

2018
c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo.
    Cell death & disease, 2014, Jan-23, Volume: 5

    Altered synaptic function is considered one of the first features of Alzheimer disease (AD). Currently, no treatment is available to prevent the dysfunction of excitatory synapses in AD. Identification of the key modulators of synaptopathy is of particular significance in the treatment of AD. We here characterized the pathways leading to synaptopathy in TgCRND8 mice and showed that c-Jun N-terminal kinase (JNK) is activated at the spine prior to the onset of cognitive impairment. The specific inhibition of JNK, with its specific inhibiting peptide D-JNKI1, prevented synaptic dysfunction in TgCRND8 mice. D-JNKI1 avoided both the loss of postsynaptic proteins and glutamate receptors from the postsynaptic density and the reduction in size of excitatory synapses, reverting their dysfunction. This set of data reveals that JNK is a key signaling pathway in AD synaptic injury and that its specific inhibition offers an innovative therapeutic strategy to prevent spine degeneration in AD.

    Topics: Alzheimer Disease; Animals; Disease Models, Animal; Female; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Transgenic; Peptides; Signal Transduction; Synapses

2014
JNK regulates APP cleavage and degradation in a model of Alzheimer's disease.
    Neurobiology of disease, 2009, Volume: 33, Issue:3

    Secretion of Amyloid-beta peptide (Abeta) circulating oligomers and their aggregate forms derived by processing of beta-amyloid precursor protein (APP) are a key event in Alzheimer's disease (AD). We show that phosphorylation of APP on threonine 668 may play a role in APP metabolism in H4-APP(sw) cell line, a degenerative AD model. We proved that JNK plays a fundamental role in this phosphorylation since its specific inhibition, with the JNK inhibitor peptide (D-JNKI1), induced APP degradation and prevented APP phosphorylation at T668. This results in a significant drop of betaAPPs, Abeta fragments and Abeta circulating oligomers. Moreover the D-JNKI1 treatment produced a switch in the APP metabolism, since the peptide reduced the rate of the amyloidogenic processing in favour of the non-amyloidogenic one. All together our results suggest an important link between APP metabolism and the JNK pathway and contribute to shed light on the molecular signalling pathway of this disease indicating JNK as an innovative target for AD therapy.

    Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Cell Line, Tumor; Cell Survival; Enzyme-Linked Immunosorbent Assay; Fluoroimmunoassay; Humans; Immunoblotting; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mutation; Peptide Fragments; Peptides; Phosphorylation; Protease Nexins; Receptors, Cell Surface

2009